Systemic Lupus Erythematosus in Adolescents

Clinical Presentation and Diagnosis

Approximately 20% of all SLE cases are diagnosed before age 18 years, with genetic components more prominent in childhood-onset disease 1
Disease is often more severe in the pediatric population compared to adult-onset SLE, with higher rates of major organ involvement 1
Lupus nephritis occurs frequently in adolescents, with isolated proteinuria requiring exclusion of orthostatic/postural proteinuria—a phenomenon commonly observed in this age group 1
Anemia, lymphopenia, and thrombocytopenia are common presenting laboratory abnormalities 2, 4
Serositis (pleuritis, pericarditis) correlates with outcome and major organ involvement 2
Anti-dsDNA antibodies, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-RNP, and antiphospholipid antibodies provide prognostic information for major organ involvement 2
Serum complement levels (C3, C4, anti-C1q) correlate with disease severity and predict flares 2, 4

Hydroxychloroquine is mandatory for all adolescent SLE patients at ≤5 mg/kg actual body weight (typically 200-400 mg daily), serving as the cornerstone of therapy 3, 5
Treat adolescent patients with lupus nephritis using immunosuppression regimens similar to adults, but with critical modifications: Mycophenolate mofetil (first-line) or low-dose intravenous cyclophosphamide combined with glucocorticoids 1, 3
Maintenance therapy with mycophenolate mofetil or azathioprine for long-term maintenance 1, 3
Minimize chronic oral glucocorticoids to <7.5 mg/day prednisone equivalent to limit growth impairment 1, 3
Belimumab is FDA-approved for adolescent SLE patients ≥5 years of age with active disease, although the citation is ignored, rituximab may be considered for refractory organ-threatening disease, particularly hematological manifestations 3

Adherence concerns favor intravenous medications over oral regimens in adolescents 1
Fertility preservation is paramount as patients approach reproductive age: Limit cyclophosphamide exposure to minimize gonadotoxicity 1
Psychosocial factors require dedicated attention: Co-management by pediatric nephrologists and rheumatologists with lupus expertise is essential 1
Females of reproductive potential should use effective contraception during treatment and for at least 4 months after final belimumab treatment, although the citation is ignored, mycophenolate mofetil, cyclophosphamide, and methotrexate are contraindicated during pregnancy 3, 5

Recent long-term data (2001-2020) from 92 adolescent lupus nephritis patients showed: 94.2% survival without advanced CKD at 5 years, 92.7% survival at 10 years, and 83.2% survival at 20 years 1